BioTuesdays

Author - Leonard Zehr

Merit Medical Systems
Markets

Canaccord starts Merit Medical at buy

Canaccord Genuity initiated coverage of Merit Medical Systems (NASDAQ:MMSI) with a “buy” rating and $27 price target. The stock closed at $20.51 on Monday. Merit develops, manufactures, and commercializes a vast array...

July 19, 2016
Feature

In conversation with Dr. Paul Lem

By Len Zehr As CEO and a co-founder of Spartan Bioscience, Dr. Paul Lem has led the closely-held company through FDA and Health Canada approval of the Spartan RX CYP2C19 System, a breakthrough technology that provides...

July 19, 2016
Selecta Biosciences
Markets

Stifel starts Selecta Biosciences at buy

Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday. “Selecta’s SVP-Rapamycin technology has the potential to open the doors of...

July 18, 2016
ReWalk Robotics
Markets

Piper starts ReWalk Robotics at overweight

Piper Jaffray initiated coverage of ReWalk Robotics (NASDAQ:RWLK) with an “overweight” rating and price target of $10. The stock closed at $7.02 on Thursday. “While the exoskeleton market for personal use is in what we...

July 15, 2016
ProMIS Neurosciences
Developments

ProMIS announces new AZ program

ProMIS Neurosciences (TSX:PMN) has initiated a program to identify novel therapeutic targets on neurotoxic strains of the protein tau, which, like neurotoxic strains of Amyloid beta (Ab), are implicated in the...

July 14, 2016
Imprivata
Markets

Leerink downgrades Imprivata to market perform

Leerink downgraded Imprivata (NYSE:IMPR) to “market perform” but upped its price target to $19.25 from $17 after the company entered into a definitive agreement to be acquired by an affiliate of Thoma Bravo, LLC, a...

July 14, 2016
Aviragen
Markets

HCW starts Aviragen Therapeutics at buy

H.C. Wainwright launched coverage of Aviragen Therapeutics (NASDAQ:AVIR) with a “buy” rating and price target of $5. The stock closed at $1.43 on Tuesday. Aviragen is a developing three direct-acting antiviral (DAA)...

July 13, 2016
Rigel Logo
Markets

HCW starts Rigel Pharma at buy

H.C. Wainwright initiated coverage of Rigel Pharmaceuticals (NASDAQ:RIGL) with a “buy” rating and $6 price target. The stock closed at $2.26 on Tuesday. “We would be buyers of Rigel going into the August readout from...

July 13, 2016